Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BeOne Medicines's Enterprise Value is $37,436 Mil.
BeOne Medicines's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $1,484 Mil. Therefore, BeOne Medicines's EV-to-OCF for today is 25.23.
The historical rank and industry rank for BeOne Medicines's EV-to-OCF or its related term are showing as below:
ONC'
s EV-to-OCF Range Over the Past 10 Years
Min: -195.85 Med: -12.32 Max: 547.04
Current: 25.23
During the past 13 years, the highest EV-to-OCF of BeOne Medicines was 547.04. The lowest was -195.85. And the median was -12.32.
ONC's EV-to-OCF is ranked worse than 90.57% of 1410
companies
in the Biotechnology industry
Industry Median: -3.625
vs ONC: 25.23
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BeOne Medicines's PE Ratio (TTM) for today is calculated as:
BeOne Medicines's share price for today is $347.48.
BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BeOne Medicines EV-to-OCF Related Terms
BeOne Medicines EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's EV-to-OCF falls into.
BeOne Medicines's current Enterprise Value is $37,436 Mil.
BeOne Medicines's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,484 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a EV-to-OCF of 25.23 as of Aug. 17, 2026. According to the industry distribution chart, BeOne Medicines ranks #1277 out of 1410 companies in the Biotechnology industry, placing it in the top 90.6%.
Is BeOne Medicines' EV-to-OCF too high?
BeOne Medicines' current EV-to-OCF is 25.23. Based on the distribution chart, BeOne Medicines ranks #1277 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EV-to-OCF compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #1277 out of 1410 companies for EV-to-OCF. This places BeOne Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BeOne Medicines's current EV-to-OCF is 25.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $375.32, compared to a current price of $347.48 — trading 7.4% below its estimated fair value. The current EV-to-OCF is 25.23. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BeOne Medicines (ONC), the current EV-to-OCF is 25.23 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $347.48 is trading 7.4% below its estimated GF Value™ of $375.32.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for ONC:
EV-to-OCF: 25.23
GF Value™: $375.32 vs. price of $347.48 (7.4% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for ONC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
